{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-13T12:52:45.056910+00:00","company":{"ticker":"LFCR","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE"},"pagination":{"limit":100,"returned":69,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Alcon Research, LLC","detail":"supply","count":5,"first_seen":"2023-05-23T23:59:59+00:00","last_seen":"2024-05-08T23:59:59+00:00","evidence_fact_ids":[50467,82789,82791,82792,148490]},{"display_name":"BMO Harris Bank, N.A.","detail":"credit_facility","count":2,"first_seen":"2023-05-23T23:59:59+00:00","last_seen":"2024-01-05T23:59:59+00:00","evidence_fact_ids":[82790,148492]},{"display_name":"BMO Bank N.A.","detail":"credit_facility","count":1,"first_seen":"2024-05-14T23:59:59+00:00","last_seen":"2024-05-14T23:59:59+00:00","evidence_fact_ids":[45730]},{"display_name":"Goldman Sachs Specialty Lending Group, L.P.","detail":"credit_facility","count":1,"first_seen":"2023-05-23T23:59:59+00:00","last_seen":"2023-05-23T23:59:59+00:00","evidence_fact_ids":[148491]},{"display_name":"Yucatan Acquisition Holdings LLC, Yucatan Foods, LLC, Camden Fruit Corp.","detail":"asset_purchase","count":1,"first_seen":"2023-02-07T23:59:59+00:00","last_seen":"2023-02-07T23:59:59+00:00","evidence_fact_ids":[181094]},{"display_name":"entities affiliated with Wynnefield Capital, Inc.","detail":"equity_purchase","count":1,"first_seen":"2022-11-25T23:59:59+00:00","last_seen":"2022-11-25T23:59:59+00:00","evidence_fact_ids":[194331]},{"display_name":"investors named therein","detail":"equity_purchase","count":1,"first_seen":"2023-01-10T23:59:59+00:00","last_seen":"2023-01-10T23:59:59+00:00","evidence_fact_ids":[186676]}],"lender":[{"display_name":"Alcon Research, LLC","detail":"term_loan","count":1,"first_seen":"2023-05-23T23:59:59+00:00","last_seen":"2023-05-23T23:59:59+00:00","evidence_fact_ids":[148496]}],"ma_counterparty":[{"display_name":"Yucatan Acquisition Holdings LLC","detail":"disposition","count":1,"first_seen":"2023-02-07T23:59:59+00:00","last_seen":"2023-02-07T23:59:59+00:00","evidence_fact_ids":[181099]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"74902017809cba216aab629833215b1fb6368bdd","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-06-05T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"To approve the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":"10,697,326","subject":null,"votes_abstain":"13,086","votes_against":"392,825","votes_for":"22,724,492","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved To approve the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan. at the 2026-06-04 meeting.","evidence_excerpt":"4.Stockholders approved the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan, with votes as follows: Votes For Votes Against Abstain Broker Non-Votes 22,724,492 392,825 13,086 10,697,326","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000023","anchor_url":"https://secwatch.observer/filing/0001005286-26-000023#claim-74902017809cba216aab629833215b1fb6368bdd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/0001005286-26-000023-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1ff13961f21b30db6d870817d96b3b8944b26ea3","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-06-05T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Non-binding advisory proposal approving the compensation of the Company's named executive officers.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"10,697,326","subject":null,"votes_abstain":"12,851","votes_against":"178,868","votes_for":"22,938,684","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Non-binding advisory proposal approving the compensation of the Company's named executive officers. at the 2026-06-04 meeting.","evidence_excerpt":"3. Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: Votes For Votes Against Abstain Broker Non-Votes 22,938,684 178,868 12,851 10,697,326","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000023","anchor_url":"https://secwatch.observer/filing/0001005286-26-000023#claim-1ff13961f21b30db6d870817d96b3b8944b26ea3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/0001005286-26-000023-index.htm"},{"fact_type":"shareholder_vote","fact_key":"68dfc713d88531900c01c63680b340efcd044d64","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-06-05T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"3,405","votes_against":"63,445","votes_for":"33,760,879","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-04 meeting.","evidence_excerpt":"2. Stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026, with votes as follows: Votes For Votes Against Abstain 33,760,879 63,445 3,405","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000023","anchor_url":"https://secwatch.observer/filing/0001005286-26-000023#claim-68dfc713d88531900c01c63680b340efcd044d64","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/0001005286-26-000023-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8ac875bcec123ca7bfe4c4d2c03d54f471981086","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-06-05T20:10:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Election of nine directors","proposal_type":"director_election","results":[{"broker_non_votes":"10,697,326","subject":"Katrina L. Houde","votes_abstain":null,"votes_against":"3,336,694","votes_for":"19,790,359","votes_withheld":"3,350"},{"broker_non_votes":"10,697,326","subject":"Humberto C. Antunes","votes_abstain":null,"votes_against":"1,408,873","votes_for":"21,713,661","votes_withheld":"7,869"},{"broker_non_votes":"10,697,326","subject":"Paul H. Johnson","votes_abstain":null,"votes_against":"1,206,182","votes_for":"21,920,254","votes_withheld":"3,967"},{"broker_non_votes":"10,697,326","subject":"Paul Josephs","votes_abstain":null,"votes_against":"57,729","votes_for":"23,068,707","votes_withheld":"3,967"},{"broker_non_votes":"10,697,326","subject":"Matthew E. Korenberg","votes_abstain":null,"votes_against":"1,693,825","votes_for":"21,432,586","votes_withheld":"3,992"},{"broker_non_votes":"10,697,326","subject":"Nelson Obus","votes_abstain":null,"votes_against":"1,675,206","votes_for":"21,450,647","votes_withheld":"4,550"},{"broker_non_votes":"10,697,326","subject":"Joshua E. Schechter","votes_abstain":null,"votes_against":"2,731,575","votes_for":"20,394,278","votes_withheld":"4,550"},{"broker_non_votes":null,"subject":"Jason Aryeh","votes_abstain":null,"votes_against":null,"votes_for":"28,287","votes_withheld":null},{"broker_non_votes":null,"subject":"Christopher S. Kiper","votes_abstain":null,"votes_against":null,"votes_for":"28,287","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Election of nine directors at the 2026-06-04 meeting.","evidence_excerpt":"1. Stockholders elected the nine director nominees and the voting results were as follows: Directors Elected by All Stockholders Votes For Votes Against Votes Withheld Broker Non-Votes Katrina L. Houde 19,790,359 3,336,694 3,350 10,697,326 Humberto C. Antunes 21,713,661 1,408,873 7,869 10,697,326 Paul H. Johnson 21,920,254 1,206,182 3,967 10,697,326 Paul Josephs 23,068,707 57,729 3,967 10,697,326 Matthew E. Korenberg 21,432,586 1,693,825 3,992 10,697,326 Nelson Obus 21,450,647 1,675,206 4,550 10,697,326 Joshua E. Schechter 20,394,278 2,731,575 4,550 10,697,326 Directors Elected by the Series A Preferred Stockholders Votes For Votes Against Votes Withheld Broker Non-Votes Jason Aryeh 28,287 — — — Christopher S. Kiper 28,287 — — —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000023","anchor_url":"https://secwatch.observer/filing/0001005286-26-000023#claim-8ac875bcec123ca7bfe4c4d2c03d54f471981086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/0001005286-26-000023-index.htm"},{"fact_type":"earnings_release","fact_key":"e70c72e62532c2b355c5ac12170016a5a98baa9c","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.43 of loss per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$15.0 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$23.2 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE reported first quarter ended March 31, 2026 results: revenue $23.2 million, net income $15.0 million, EPS $0.43 of loss per diluted share. Guidance reaffirmed.","evidence_excerpt":"the year,” stated Paul Josephs, President and Chief Executive Officer of Lifecore. Financial Snapshot and Recent Developments • Revenues for the first quarter of 2026 were $23.2 million , a decrease of $12.0 million, or 34%, compared to $35.2 million for the comparable prior year quarter ended February 23, 2025. • Gross profit margin for the first quarter of","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-26-000018","anchor_url":"https://secwatch.observer/filing/0001005286-26-000018#claim-e70c72e62532c2b355c5ac12170016a5a98baa9c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm"},{"fact_type":"earnings_release","fact_key":"544dd2a8570b35d5085f8ee02d49778eb3f20793","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-03-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$18.0 million","period_text":"the transition period ended December 31, 2025","report_date":"2026-03-16","result_type":"reported_results","revenue_text":"$75.5 Million"},"claim":"LIFECORE BIOMEDICAL, INC. DE reported the transition period ended December 31, 2025 results: revenue $75.5 Million, net income $18.0 million.","evidence_excerpt":"Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- --","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000007","anchor_url":"https://secwatch.observer/filing/0001005286-26-000007#claim-544dd2a8570b35d5085f8ee02d49778eb3f20793","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"94cc79b192aeacc37743a8da9fec743b7c765ffd","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-03-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2025","report_date":"2026-03-16","result_type":"reported_results","revenue_text":"$35.7 Million"},"claim":"LIFECORE BIOMEDICAL, INC. DE reported the fourth quarter ended December 31, 2025 results: revenue $35.7 Million.","evidence_excerpt":"Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-26-000007","anchor_url":"https://secwatch.observer/filing/0001005286-26-000007#claim-94cc79b192aeacc37743a8da9fec743b7c765ffd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm"},{"fact_type":"auditor_change","fact_key":"958481bf39510d8d24f8ba25a2baa57d40b75465","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2025-08-18T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BDO USA, P.C.","disagreement_text":null,"effective_date":"2025-08-12","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"KPMG LLP"},"claim":"LIFECORE BIOMEDICAL, INC. DE dismissed BDO USA, P.C. as its auditor.","evidence_excerpt":"Dismissal of Independent Registered Public Accounting Firm On August 12, 2025, the Audit Committee approved the dismissal of BDO USA, P.C. (“BDO”), the Company’s current independent registered public accounting firm, and BDO was dismissed on that date. BDO’s audit reports on the Company’s consolidated financial statements as of and for the fiscal years ended May 26, 2024 and May 25, 2025 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-25-000118","anchor_url":"https://secwatch.observer/filing/0001005286-25-000118#claim-958481bf39510d8d24f8ba25a2baa57d40b75465","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000118/0001005286-25-000118-index.htm"},{"fact_type":"auditor_change","fact_key":"b0b23fafbd97b7b4f395416f5581a167ca168f10","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2025-08-18T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2025-08-12","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"LIFECORE BIOMEDICAL, INC. DE engaged KPMG LLP as its auditor.","evidence_excerpt":"Engagement of New Independent Registered Public Accounting Firm On August 12, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of Lifecore Biomedical (the “Company”) concluded its process to select the Company’s independent registered public accounting firm for the Company’s transition period beginning May 26, 2025 and ending December 31, 2025. Based on its review and evaluation, on August 12, 2025, the Audit Committee approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the transition period ending December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-25-000118","anchor_url":"https://secwatch.observer/filing/0001005286-25-000118#claim-b0b23fafbd97b7b4f395416f5581a167ca168f10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000118/0001005286-25-000118-index.htm"},{"fact_type":"executive_change","fact_key":"ad15fca4b3","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-09-23T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ray Diradoorian departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Ray Diradoorian notified the Company that he intends to resign as a director of the Board effective as of immediately prior to the Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000138","anchor_url":"https://secwatch.observer/filing/0001005286-24-000138#claim-ad15fca4b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000138/0001005286-24-000138-index.htm"},{"fact_type":"executive_change","fact_key":"58f9087dfb","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-09-23T23:59:59+00:00","payload":{"action":"not standing for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jeffrey L. Edwards departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Jeffrey L. Edwards notified Lifecore Biomedical, Inc. (the “Company”) that he has elected not to stand for re-election to serve as a director of the Board of Directors of the Company (the “Board”) at the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000138","anchor_url":"https://secwatch.observer/filing/0001005286-24-000138#claim-58f9087dfb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000138/0001005286-24-000138-index.htm"},{"fact_type":"executive_change","fact_key":"f3de27d65e","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-29T23:59:59+00:00","payload":{"action":"employment will end","action_category":"departure","departure_tone":"termination","effective_date":"2024-09-02","interim":false,"role":"Chief Financial Officer and Secretary","role_category":"cfo","successor_name":"Ryan D. Lake","successor_named":true},"claim":"John D. Morberg departed as Chief Financial Officer and Secretary at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Mr. Morberg's separation will be treated as a termination by the Company without Cause subsequent to a Change in Control under that certain Executive Employment Agreement (the \"Morberg Employment Agreement\"), dated January 19, 2021, between the Company and Mr. Morberg","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-24-000128","anchor_url":"https://secwatch.observer/filing/0001005286-24-000128#claim-f3de27d65e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000128/0001005286-24-000128-index.htm"},{"fact_type":"executive_change","fact_key":"ba19dafb14","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-03","interim":false,"role":"Chief Financial Officer and Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ryan D. Lake was appointed as Chief Financial Officer and Secretary at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On August 28, 2024, the Company appointed Ryan D. Lake as the Company’s Chief Financial Officer and Secretary, effective September 3, 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-24-000128","anchor_url":"https://secwatch.observer/filing/0001005286-24-000128#claim-ba19dafb14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000128/0001005286-24-000128-index.htm"},{"fact_type":"executive_change","fact_key":"569ea6b333","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Matthew Korenberg was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000119","anchor_url":"https://secwatch.observer/filing/0001005286-24-000119#claim-569ea6b333","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000119/0001005286-24-000119-index.htm"},{"fact_type":"executive_change","fact_key":"2d89695feb","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Humberto C. Antunes was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000119","anchor_url":"https://secwatch.observer/filing/0001005286-24-000119#claim-2d89695feb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000119/0001005286-24-000119-index.htm"},{"fact_type":"executive_change","fact_key":"37329f9a75","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Paul H. Johnson was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000119","anchor_url":"https://secwatch.observer/filing/0001005286-24-000119#claim-37329f9a75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000119/0001005286-24-000119-index.htm"},{"fact_type":"executive_change","fact_key":"b62a862780","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-08-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jason Aryeh was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"the Board appointed Jason Aryeh, Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000119","anchor_url":"https://secwatch.observer/filing/0001005286-24-000119#claim-b62a862780","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000119/0001005286-24-000119-index.htm"},{"fact_type":"restructuring_charge","fact_key":"20208d7cf9f259b7b4bcc2a947ac2650e2c81d7c","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-07-12T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $1.0 million","effective_date":"2024-07-08","event_type":"restructuring","headcount_text":"46 full-time employees of the Company, representing approximately 9% of the Company’s workforce","item_codes_triggered":["2.05"]},"claim":"LIFECORE BIOMEDICAL, INC. DE announced a restructuring with charges of approximately $1.0 million (46 full-time employees of the Company, representing approximately 9% of the Company’s workforce).","evidence_excerpt":"On July 8, 2024, Lifecore Biomedical, Inc. (the “Company”) determined to implement a strategic reduction of the Company’s workforce (the “Workforce Reduction Plan”) to terminate 46 full-time employees of the Company, representing approximately 9% of the Company’s workforce, as part of an initiative to strategically optimize the Company’s cost structure. In connection with the Workforce Reduction Plan, the Company estimates that it will incur termination benefit costs of approximately $1.0 million, which primarily consist of one-time severance benefits.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000086","anchor_url":"https://secwatch.observer/filing/0001005286-24-000086#claim-20208d7cf9f259b7b4bcc2a947ac2650e2c81d7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000086/0001005286-24-000086-index.htm"},{"fact_type":"executive_change","fact_key":"eeb6b037f7","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Matthew Korenberg was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000081","anchor_url":"https://secwatch.observer/filing/0001005286-24-000081#claim-eeb6b037f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000081/0001005286-24-000081-index.htm"},{"fact_type":"executive_change","fact_key":"0e1d2da00b","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Humberto C. Antunes was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000081","anchor_url":"https://secwatch.observer/filing/0001005286-24-000081#claim-0e1d2da00b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000081/0001005286-24-000081-index.htm"},{"fact_type":"executive_change","fact_key":"5287d4d52f","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Paul H. Johnson was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000081","anchor_url":"https://secwatch.observer/filing/0001005286-24-000081#claim-5287d4d52f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000081/0001005286-24-000081-index.htm"},{"fact_type":"executive_change","fact_key":"f271c912e4","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-05-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-20","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Paul Josephs was appointed as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On May 20, 2024, Paul Josephs began serving as the Company’s President and Chief Executive Officer and was elected as a director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000071","anchor_url":"https://secwatch.observer/filing/0001005286-24-000071#claim-f271c912e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000071/0001005286-24-000071-index.htm"},{"fact_type":"executive_change","fact_key":"6d629bd1eb","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-05-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-19","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Paul Josephs","successor_named":true},"claim":"James G. Hall resigned as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Effective May 19, 2024, James G. Hall resigned as a director of the Company and ceased serving as the Company’s President and Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000071","anchor_url":"https://secwatch.observer/filing/0001005286-24-000071#claim-6d629bd1eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000071/0001005286-24-000071-index.htm"},{"fact_type":"material_agreement","fact_key":"933001da481db8a9a7a31cf651cabbe333114e66","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-05-14T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Seventh Amendment to Credit Agreement","agreement_type":"credit_facility","counterparty":"BMO Bank N.A.","effective_date":"2024-05-10","item_codes_triggered":["1.01"],"value_text":"Established FILO tranche of revolving loans with interest at SOFR plus 4.25%, monthly FILO Cap reduc"},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Seventh Amendment to Credit Agreement with BMO Bank N.A. valued at Established FILO tranche of revolving loans with interest at SOFR plus 4.25%, monthly FILO Cap reduc (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Lifecore Biomedical, Inc. (the “ Company ”), Curation Foods, Inc. (“ Curation ”) and Lifecore Biomedical Operating Company, Inc. (together with the Company and Curation, the “ Borrowers ”), and BMO Bank N.A. (f/k/a BMO Harris Bank N.A.) (“ BMO ”) entered into that certain Seventh Amendment to Credit Agreement (the “ FILO Amendment ”), which amended that certain Credit Agreement, dated as of December 31, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date of the FILO Amendment, the “ ABL Credit Agreement ” and the ABL Credit Agreement, as amended by the FILO Amendment, the “ Amended ABL Credit Agreement ”), by and among, inter alios, the Borrowers and BMO.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000062","anchor_url":"https://secwatch.observer/filing/0001005286-24-000062#claim-933001da481db8a9a7a31cf651cabbe333114e66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000062/0001005286-24-000062-index.htm"},{"fact_type":"material_agreement","fact_key":"5006d6a8af20eb25eceb014f9ae489e60a47edd0","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1","agreement_type":"supply","counterparty":"Alcon Research, LLC","effective_date":"2024-05-02","item_codes_triggered":["1.01"],"value_text":"$5,500,000"},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Amendment No. 1 with Alcon Research, LLC valued at $5,500,000 (effective 2024-05-02).","evidence_excerpt":"On May 2, 2024, Lifecore Biomedical, LLC, a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into Amendment No. 1 (the “ARCMA Amendment”) to Amended and Restated Contract Manufacturing Agreement with Alcon Research, LLC (the “ARCMA”), under which Alcon made a prepayment in the amount of $5,500,000 toward future purchases of products under the ARCMA.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000059","anchor_url":"https://secwatch.observer/filing/0001005286-24-000059#claim-5006d6a8af20eb25eceb014f9ae489e60a47edd0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000059/0001005286-24-000059-index.htm"},{"fact_type":"auditor_change","fact_key":"f54678b90847631844f57377be33dc3344318ba3","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"BDO USA, P.C.","disagreement_text":null,"effective_date":"2024-04-29","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"LIFECORE BIOMEDICAL, INC. DE engaged BDO USA, P.C. as its auditor.","evidence_excerpt":"On April 29, 2024, the Audit Committee of the Board of Directors of Lifecore Biomedical, Inc. (the “Company”) approved the engagement of BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm, effective immediately, to perform audit services for the fiscal year ending May 26, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000054","anchor_url":"https://secwatch.observer/filing/0001005286-24-000054#claim-f54678b90847631844f57377be33dc3344318ba3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000054/0001005286-24-000054-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"bfb2b7de31718be9c252fa2ed204452e13511283","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-04-19T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-04-15","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"and November 29, 2023 (the “Q1 Form 10-Q” and “Q2 Form 10-Q,” respectively, and together with the Q3 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company’s continued listing on Nasdaq Global Select Market . The Notice has no immediate effect on the listing or trading","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000050","anchor_url":"https://secwatch.observer/filing/0001005286-24-000050#claim-bfb2b7de31718be9c252fa2ed204452e13511283","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000050/0001005286-24-000050-index.htm"},{"fact_type":"executive_change","fact_key":"b853dc6880","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-03-21T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Paul Josephs was elected as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Mr. Josephs will be elected to the Board of Directors of the Company (the “Board”) to the vacancy caused by the resignation of Mr. Hall on the later of the Effective Date or the date of the Annual Meeting","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000036","anchor_url":"https://secwatch.observer/filing/0001005286-24-000036#claim-b853dc6880","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm"},{"fact_type":"executive_change","fact_key":"999790bbbc","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-03-21T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-20","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Paul Josephs","successor_named":true},"claim":"James G. Hall resigned as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Mr. Josephs will succeed James G. Hall, the Company’s current President and Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000036","anchor_url":"https://secwatch.observer/filing/0001005286-24-000036#claim-999790bbbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm"},{"fact_type":"executive_change","fact_key":"75713d6165","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-03-21T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-20","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Paul Josephs was elected as President and Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Paul Josephs has been elected as the Company’s President and Chief Executive Officer effective May 20, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000036","anchor_url":"https://secwatch.observer/filing/0001005286-24-000036#claim-75713d6165","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000036/0001005286-24-000036-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6ac54c5df6a749919d94ed94515ec950c57a7b15","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-02-16T23:59:59+00:00","payload":{"company_response":"intends to appeal","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2024-02-13","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"February 13, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchang","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000020","anchor_url":"https://secwatch.observer/filing/0001005286-24-000020#claim-6ac54c5df6a749919d94ed94515ec950c57a7b15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000020/0001005286-24-000020-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"34c9892d50a0e8524a59a94c2499c63ab94df50f","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-01-12T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-02-12","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2024-01-10","notice_type":"noncompliance_notice","plan_due_date":"2024-01-25","raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"10-Q for the fiscal quarter ended August 27, 2023 (the “Q1 Form 10-Q” and, together with the Form 10-K and the Q2 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. On October 16, 2023, the Company submitted to Nasdaq its compliance plan (the “Compliance Plan”) with respect to the filing of the Form 10-K","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-24-000013","anchor_url":"https://secwatch.observer/filing/0001005286-24-000013#claim-34c9892d50a0e8524a59a94c2499c63ab94df50f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000013/0001005286-24-000013-index.htm"},{"fact_type":"material_agreement","fact_key":"390dde0c0887e936db6d33d7093dbdd50d0ecb6b","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1 to Amended and Restated Supply Agreement","agreement_type":"supply","counterparty":"Alcon Research, LLC","effective_date":"2023-12-31","item_codes_triggered":["1.01"],"value_text":"Amendment providing Alcon option to purchase a filter dryer; revised capacity and purchase commitmen"},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Amendment No. 1 to Amended and Restated Supply Agreement with Alcon Research, LLC valued at Amendment providing Alcon option to purchase a filter dryer; revised capacity and purchase commitmen (effective 2023-12-31).","evidence_excerpt":"On December 31, 2023, the Company entered into Amendment No. 1 (the “Supply Agreement Amendment”) to that certain Amended and Restated Supply Agreement (the “Supply Agreement”), dated May 3, 2023, with Alcon, related to the Company’s manufacture and supply of sodium hyaluronate (“HA”) for Alcon.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000004","anchor_url":"https://secwatch.observer/filing/0001005286-24-000004#claim-390dde0c0887e936db6d33d7093dbdd50d0ecb6b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000004/0001005286-24-000004-index.htm"},{"fact_type":"material_agreement","fact_key":"4e004307e397607083a7e8330b4d3f7675b66d25","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Amended and Restated Contract Manufacturing Agreement","agreement_type":"supply","counterparty":"Alcon Research, LLC","effective_date":"2023-12-31","item_codes_triggered":["1.01"],"value_text":"Amended and restated contract manufacturing agreement; initial term expires December 31, 2031"},"claim":"LIFECORE BIOMEDICAL, INC. DE entered into Amended and Restated Contract Manufacturing Agreement with Alcon Research, LLC valued at Amended and restated contract manufacturing agreement; initial term expires December 31, 2031 (effective 2023-12-31).","evidence_excerpt":"On December 31, 2023, the Company entered into that certain Amended and Restated Contract Manufacturing Agreement (the “Amended and Restated CMA”), with Alcon, which amended and restated the existing contract manufacturing agreement between the Company and Alcon related to the Company’s aseptic manufacturing of a variety of ophthalmic viscoelastic injection devices.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000004","anchor_url":"https://secwatch.observer/filing/0001005286-24-000004#claim-4e004307e397607083a7e8330b4d3f7675b66d25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000004/0001005286-24-000004-index.htm"},{"fact_type":"material_agreement","fact_key":"315d1fda65b7ad17dc892f47d1b38ed33cbf9b10","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Limited Waiver and Sixth Amendment to Credit Agreement","agreement_type":"credit_facility","counterparty":"BMO Harris Bank, N.A.","effective_date":"2023-12-31","item_codes_triggered":["1.01"],"value_text":"Waiver of defaults and amendments to Revolving Credit Agreement"},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Limited Waiver and Sixth Amendment to Credit Agreement with BMO Harris Bank, N.A. valued at Waiver of defaults and amendments to Revolving Credit Agreement (effective 2023-12-31).","evidence_excerpt":"On December 31, 2023, Lifecore Biomedical, Inc. (the “Company”) entered into (i) that certain Limited Waiver and First Amendment to Credit and Guaranty Agreement (the “Alcon Amendment”), by and among Alcon Research, LLC (“Alcon”), the Company, and certain subsidiaries of the Company, which amended that certain Credit and Guaranty Agreement, dated May 22, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the Alcon Amendment, the “Term Loan Credit Agreement”), by and among the Company, Curation Foods, Inc. (“Curation”) and Lifecore Biomedical Operating Company, Inc. (“Lifecore” and, together with the Company and Curation, the “Borrowers”), certain of the Company’s other subsidiaries, as guarantors, and Alcon, as administrative agent, collateral agent and lender, and (ii) that certain Limited Waiver and Sixth Amendment to Credit Agreement (the “BMO Amendment” and, together with the Alcon Amendment, the “Credit Agreement Amendments”) by and among","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000004","anchor_url":"https://secwatch.observer/filing/0001005286-24-000004#claim-315d1fda65b7ad17dc892f47d1b38ed33cbf9b10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000004/0001005286-24-000004-index.htm"},{"fact_type":"material_agreement","fact_key":"1d46cf73aa3e6fa42c112d9dcb60d30e4230e183","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Limited Waiver and First Amendment to Credit and Guaranty Agreement","agreement_type":"credit_facility","counterparty":"Alcon Research, LLC","effective_date":"2023-12-31","item_codes_triggered":["1.01"],"value_text":"Waiver of defaults and amendments to Term Loan Credit Agreement"},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Limited Waiver and First Amendment to Credit and Guaranty Agreement with Alcon Research, LLC valued at Waiver of defaults and amendments to Term Loan Credit Agreement (effective 2023-12-31).","evidence_excerpt":"On December 31, 2023, Lifecore Biomedical, Inc. (the “Company”) entered into (i) that certain Limited Waiver and First Amendment to Credit and Guaranty Agreement (the “Alcon Amendment”), by and among Alcon Research, LLC (“Alcon”), the Company, and certain subsidiaries of the Company, which amended that certain Credit and Guaranty Agreement, dated May 22, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the Alcon Amendment, the “Term Loan Credit Agreement”), by and among the Company, Curation Foods, Inc. (“Curation”) and Lifecore Biomedical Operating Company, Inc. (“Lifecore” and, together with the Company and Curation, the “Borrowers”), certain of the Company’s other subsidiaries, as guarantors, and Alcon, as administrative agent, collateral agent and lender, and (ii) that certain Limited Waiver and Sixth Amendment to Credit Agreement (the “BMO Amendment” and, together with the Alcon Amendment, the “Credit Agreement Amendments”) by and among","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-24-000004","anchor_url":"https://secwatch.observer/filing/0001005286-24-000004#claim-1d46cf73aa3e6fa42c112d9dcb60d30e4230e183","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528624000004/0001005286-24-000004-index.htm"},{"fact_type":"auditor_change","fact_key":"bc5115b8d888e52972fafdff5db366c85b7bfcc7","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-10-31T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2023-10-30","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"LIFECORE BIOMEDICAL, INC. DE reported that prior financial statements should not be relied upon.","evidence_excerpt":"lidated results as of and for the fourth quarter and fiscal year ended May 28, 2023 (“FY23”) and furnished on Form 8-K with the SEC on August 31, 2023 (the “Earnings Release”) (collectively, the “Non-Reliance Periods”), should no longer be relied upon. This determination resulted from the Company’s identification of errors in the Non-Reliance Periods related to certain adjustments as more particularly described below, involving the calculation of capitalized interest, valuation of inventories, and certain adjustments related to previously divested businesses contained in the Non-Reliance Periods. In addition, the Company expects to correct certain items that were previously identified and concluded as immaterial, individually and in the aggregate, to the financial statements for the Non-Reliance Periods. The Company has assessed the materiality of these errors in accordance with the U.S.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000118","anchor_url":"https://secwatch.observer/filing/0001005286-23-000118#claim-bc5115b8d888e52972fafdff5db366c85b7bfcc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000118/0001005286-23-000118-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"30fcf6d093c61791122df79df431d58e6395dcb6","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-10-18T23:59:59+00:00","payload":{"company_response":"submitted plan to regain compliance","compliance_status":"plan_due","cure_deadline":"2024-02-12","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-10-12","notice_type":"deficiency_notice","plan_due_date":"2023-10-16","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"n filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K” and, together with the Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. In accordance with the instructions contained in the Notice, the Company submitted a plan to regain compliance with the Listing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000116","anchor_url":"https://secwatch.observer/filing/0001005286-23-000116#claim-30fcf6d093c61791122df79df431d58e6395dcb6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000116/0001005286-23-000116-index.htm"},{"fact_type":"earnings_release","fact_key":"a0d196ca04fd5737160ea9956e8c94365d2df9c3","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-08-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss from continuing operations of $33.8 million","period_text":"the fourth quarter and full year of fiscal 2023 ended May 28, 2023","report_date":"2023-08-31","result_type":"reported_results","revenue_text":"$31.5 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE reported the fourth quarter and full year of fiscal 2023 ended May 28, 2023 results: revenue $31.5 million, net income Net loss from continuing operations of $33.8 million.","evidence_excerpt":"fiscal 2024 second quarter and to a greater degree in the second half of the fiscal year.\" LIFECORE FISCAL FOURTH QUARTER 2023 FINANCIAL HIGHLIGHTS: • Consolidated revenues of $31.5 million, an increase of 12.2% year-over-year. • Consolidated gross profit of $8.4 million, a decrease of $4.3 million, or 33.9% year-over-year • Consolidated net loss from continuing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000108","anchor_url":"https://secwatch.observer/filing/0001005286-23-000108#claim-a0d196ca04fd5737160ea9956e8c94365d2df9c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"463f1c93abf393f98a1127fd0f13d016edecb942","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-08-22T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2024-02-12","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-08-17","notice_type":"noncompliance_notice","plan_due_date":"2023-10-16","raw_rule_text":"Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 17, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate effect","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000106","anchor_url":"https://secwatch.observer/filing/0001005286-23-000106#claim-463f1c93abf393f98a1127fd0f13d016edecb942","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000106/0001005286-23-000106-index.htm"},{"fact_type":"debt_financing","fact_key":"9d8b04f7d5254d3f7deffa800231275c698c5f8d","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-05-23T23:59:59+00:00","payload":{"counterparty":"Alcon Research, LLC","effective_date":"2023-05-22","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"fixed interest rate equal to 10% per annum. Interest is payable-in-kind until th","item_codes_triggered":["2.03"],"maturity_text":"obligations under the Term Loan Credit Agreement mature on May 22, 2029","principal_text":"up to $140.0 million in term loans, which were funded in full on May 22, 2023 (the amount of which may be adjusted pursu"},"claim":"LIFECORE BIOMEDICAL, INC. DE incurred term loan of up to $140.0 million in term loans, which were funded in full on May 22, 2023 (the amount of which may be adjusted pursu with Alcon Research, LLC at fixed interest rate equal to 10% per annum. Interest is payable-in-kind until th maturing obligations under the Term Loan Credit Agreement mature on May 22, 2029.","evidence_excerpt":"The Term Loan Credit Agreement provides for up to $140.0 million in term loans, which were funded in full on May 22, 2023 (the amount of which may be adjusted pursuant to its terms following the post-closing adjustments set forth in the Equipment Sale and Leaseback Agreement (defined below)). The obligations under the Term Loan Credit Agreement mature on May 22, 2029. The Term Loan Credit Agreement is secured by the same collateral that secures the Revolving Credit Agreement (defined below), with relative priorities in respect thereof, as set forth in the Intercreditor Agreement (defined below). The loans under the Term Loan Credit Agreement have a fixed interest rate equal to 10% per annum.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000087","anchor_url":"https://secwatch.observer/filing/0001005286-23-000087#claim-9d8b04f7d5254d3f7deffa800231275c698c5f8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000087/0001005286-23-000087-index.htm"},{"fact_type":"material_agreement","fact_key":"65b63c1467b676f9ebe2cdb50ebb7be47c90e133","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-05-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Revolving Loan Amendment","agreement_type":"credit_facility","counterparty":"BMO Harris Bank, N.A.","effective_date":"2023-05-22","item_codes_triggered":["1.01"],"value_text":null},"claim":"LIFECORE BIOMEDICAL, INC. DE amended Revolving Loan Amendment with BMO Harris Bank, N.A. (effective 2023-05-22).","evidence_excerpt":"On May 22, 2023, the Borrowers and certain of the Company’s other subsidiaries, as guarantors, entered into a Limited Waiver, Consent and Fifth Amendment (the “ Revolving Loan Amendment ”) to that certain Credit Agreement (the “ Revolving Credit Agreement ”), dated as of December 31, 2020, by and among, inter alios, the Borrowers and BMO Harris Bank, N.A. (“ BMO ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000087","anchor_url":"https://secwatch.observer/filing/0001005286-23-000087#claim-65b63c1467b676f9ebe2cdb50ebb7be47c90e133","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000087/0001005286-23-000087-index.htm"},{"fact_type":"material_agreement","fact_key":"c8b4cfbc0176d18d0868776672daf675be3826f7","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-05-23T23:59:59+00:00","payload":{"action":"termination","agreement_name":null,"agreement_type":"credit_facility","counterparty":"Goldman Sachs Specialty Lending Group, L.P.","effective_date":"2023-05-22","item_codes_triggered":["1.02"],"value_text":null},"claim":"LIFECORE BIOMEDICAL, INC. DE terminated a credit facility with Goldman Sachs Specialty Lending Group, L.P. (effective 2023-05-22).","evidence_excerpt":"The Term Loan Credit Agreement refinanced in full all obligations of the Borrowers and their subsidiaries under that certain Credit and Guaranty Agreement, dated as of December 31, 2020, by and among, inter alios, the Borrowers and Goldman Sachs Specialty Lending Group, L.P., as administrative agent, collateral agent and a lender, which was terminated upon the entry into the Term Loan Credit Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000087","anchor_url":"https://secwatch.observer/filing/0001005286-23-000087#claim-c8b4cfbc0176d18d0868776672daf675be3826f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000087/0001005286-23-000087-index.htm"},{"fact_type":"material_agreement","fact_key":"70d9a8e298a9a767983fe1eea0b24e27c7df4a60","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-05-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Term Loan Credit Agreement","agreement_type":"credit_facility","counterparty":"Alcon Research, LLC","effective_date":"2023-05-22","item_codes_triggered":["1.01"],"value_text":"up to $140.0 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE entered into Term Loan Credit Agreement with Alcon Research, LLC valued at up to $140.0 million (effective 2023-05-22).","evidence_excerpt":"On May 22, 2023, Lifecore Biomedical, Inc. (the “ Company ”), Curation Foods, Inc. (“ Curation ”) and Lifecore Biomedical Operating Company, Inc. (“ Lifecore ” and, together with the Company and Curation, the “ Borrowers ”), certain of the Company’s other subsidiaries, as guarantors, and Alcon Research, LLC (“ Alcon ”), as administrative agent, collateral agent and lender, entered into that certain Credit and Guaranty Agreement (the “ Term Loan Credit Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000087","anchor_url":"https://secwatch.observer/filing/0001005286-23-000087#claim-70d9a8e298a9a767983fe1eea0b24e27c7df4a60","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000087/0001005286-23-000087-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"0fc6c75585d0ef61caf03df3639ea9e2039eefd1","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-04-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-04-13","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"April 13, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended February 26, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-23-000078","anchor_url":"https://secwatch.observer/filing/0001005286-23-000078#claim-0fc6c75585d0ef61caf03df3639ea9e2039eefd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000078/0001005286-23-000078-index.htm"},{"fact_type":"earnings_release","fact_key":"d74cd65ae67818948e0c1568b08e08659a679664","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-03-16T23:59:59+00:00","payload":{"eps_text":"$(0.42) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(12.4) million","period_text":"the fiscal 2023 second quarter ended November 27, 2022","report_date":"2023-03-16","result_type":"reported_results","revenue_text":"$38.8 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE reported the fiscal 2023 second quarter ended November 27, 2022 results: revenue $38.8 million, net income $(12.4) million, EPS $(0.42) per diluted share.","evidence_excerpt":"Foods assets are reflected as part of the Curation Foods segment in all periods presented within the Company’s financial statements reported herein. • Consolidated revenues of $38.8 million, a decrease of (10.7)% year-over-year. • Consolidated gross profit of $7.1 million, a decrease of $7.6 million, or 51.7% year-over-year, primarily due to a $5.0 million decline","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001005286-23-000059","anchor_url":"https://secwatch.observer/filing/0001005286-23-000059#claim-d74cd65ae67818948e0c1568b08e08659a679664","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm"},{"fact_type":"ma_transaction","fact_key":"45f19847934988df1be424d5b79ffe3c590da526","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-02-07T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2023-02-07","consideration_text":"$17.5 million in cash","counterparty":"Yucatan Acquisition Holdings LLC","effective_date":"2023-02-07","item_codes_triggered":["2.01"]},"claim":"LIFECORE BIOMEDICAL, INC. DE completed a disposition involving Yucatan Acquisition Holdings LLC for $17.5 million in cash (closed 2023-02-07).","evidence_excerpt":"executed by the Parties on February 7, 2023 (the “Securities Purchase Agreement”). Pursuant to the Securities Purchase Agreement, Buyer acquired Yucatan for a purchase price of $17.5 million in cash, subject to certain post-closing adjustments, including net working capital, at closing. Following the Yucatan Disposition, the Company continues to grow its Lifecore","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000037","anchor_url":"https://secwatch.observer/filing/0001005286-23-000037#claim-45f19847934988df1be424d5b79ffe3c590da526","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000037/0001005286-23-000037-index.htm"},{"fact_type":"material_agreement","fact_key":"208506b7830418a0b8455d1cf8762f7f9289be54","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-02-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Yucatan Acquisition Holdings LLC, Yucatan Foods, LLC, Camden Fruit Corp.","effective_date":"2023-02-07","item_codes_triggered":["1.01"],"value_text":null},"claim":"LIFECORE BIOMEDICAL, INC. DE entered into Securities Purchase Agreement with Yucatan Acquisition Holdings LLC, Yucatan Foods, LLC, Camden Fruit Corp. (effective 2023-02-07).","evidence_excerpt":"Securities Purchase Agreement, dated February 7, 2023, by and among Lifecore Biomedical, Inc., Yucatan Foods, LLC, Camden Fruit Corp., and Yucatan Acquisition Holdings LLC.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000037","anchor_url":"https://secwatch.observer/filing/0001005286-23-000037#claim-208506b7830418a0b8455d1cf8762f7f9289be54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000037/0001005286-23-000037-index.htm"},{"fact_type":"auditor_change","fact_key":"3e1f2325641bdcfbdb87179b6fbb0e4085a00514","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":null,"disagreement_text":null,"effective_date":"2023-01-31","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"LIFECORE BIOMEDICAL, INC. DE reported that prior financial statements should not be relied upon.","evidence_excerpt":"d financial statements as of and for the year ended May 29, 2022 and (ii) unaudited consolidated financial statements as of and for the three months ended August 28, 2022 (collectively, the “Prior Financial Statements”) should no longer be relied upon. This determination resulted from the identification of errors in the Prior Financial Statements identified by the Company related to certain non-cash impairment charges related to the Company’s Curation Foods business contained in the Prior Financial Statements. The Company has assessed the materiality of these errors in accordance with the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 99 (“SAB”), Materiality and SAB No. 108, Quantifying Financial Statement Misstatements, and has concluded that the Prior Financial Statements should be restated. The restatement is not currently expected by the Company to have an adve","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000032","anchor_url":"https://secwatch.observer/filing/0001005286-23-000032#claim-3e1f2325641bdcfbdb87179b6fbb0e4085a00514","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000032/0001005286-23-000032-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"f7eff3a17f153be51063a6cf83c1cf4b5b335d01","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-01-11T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2023-07-05","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-01-11","notice_type":"deficiency_notice","plan_due_date":"2023-03-12","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"January 11, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended November 27, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediat","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000027","anchor_url":"https://secwatch.observer/filing/0001005286-23-000027#claim-f7eff3a17f153be51063a6cf83c1cf4b5b335d01","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000027/0001005286-23-000027-index.htm"},{"fact_type":"material_agreement","fact_key":"e6f4cb8214bc225bf761f61f36e661c267643234","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-01-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"investors named therein (each a \"Purchaser\" and collectively the \"Purchasers\")","effective_date":"2023-01-09","item_codes_triggered":["1.01"],"value_text":"aggregate purchase price of $38.75 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE entered into Securities Purchase Agreement with investors named therein (each a \"Purchaser\" and collectively the \"Purchasers\") valued at aggregate purchase price of $38.75 million (effective 2023-01-09).","evidence_excerpt":"On January 9, 2023, Lifecore Biomedical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (each a “Purchaser” and collectively the “Purchasers”). Pursuant to the Purchase Agreement, the Company issued and sold an aggregate of 38,750 shares (the “Preferred Shares”) of the Series A Convertible Preferred Stock, par value $0.001 per share (the “Convertible Preferred Stock”), to the Purchasers for an aggregate purchase price of $38.75 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-23-000015","anchor_url":"https://secwatch.observer/filing/0001005286-23-000015#claim-e6f4cb8214bc225bf761f61f36e661c267643234","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000015/0001005286-23-000015-index.htm"},{"fact_type":"executive_change","fact_key":"79471f7019","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christopher Kiper was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Pursuant to the Series A Director Right and effective as of the Closing Date, the Board appointed Nat Calloway, 40, to the Board as a new Class 2 director, and Christopher Kiper, 52, as a Class 1 Director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-23-000015","anchor_url":"https://secwatch.observer/filing/0001005286-23-000015#claim-79471f7019","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000015/0001005286-23-000015-index.htm"},{"fact_type":"executive_change","fact_key":"603264602a","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nat Calloway was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Pursuant to the Series A Director Right and effective as of the Closing Date, the Board appointed Nat Calloway, 40, to the Board as a new Class 2 director, and Christopher Kiper, 52, as a Class 1 Director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-23-000015","anchor_url":"https://secwatch.observer/filing/0001005286-23-000015#claim-603264602a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000015/0001005286-23-000015-index.htm"},{"fact_type":"material_agreement","fact_key":"62d751c2abec7000cb62e90046a3ffe7c914ef38","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"entities affiliated with Wynnefield Capital, Inc.","effective_date":"2022-11-25","item_codes_triggered":["1.01"],"value_text":"approximately $5.0 million"},"claim":"LIFECORE BIOMEDICAL, INC. DE entered into Securities Purchase Agreement with entities affiliated with Wynnefield Capital, Inc. valued at approximately $5.0 million (effective 2022-11-25).","evidence_excerpt":"On November 25, 2022, Lifecore Biomedical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with Wynnefield Capital, Inc. (the “Purchasers”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000083","anchor_url":"https://secwatch.observer/filing/0001005286-22-000083#claim-62d751c2abec7000cb62e90046a3ffe7c914ef38","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000083/0001005286-22-000083-index.htm"},{"fact_type":"governance_change","fact_key":"95627fccc5bc5faaf6c7035b3c7c105972d157da","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-16T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2022-11-14","item_codes_triggered":["5.03"],"summary_text":"Amended the Amended and Restated Bylaws solely to reflect the name change to Lifecore Biomedical, Inc."},"claim":"LIFECORE BIOMEDICAL, INC. DE: Amended the Amended and Restated Bylaws solely to reflect the name change to Lifecore Biomedical, Inc (effective 2022-11-14).","evidence_excerpt":"Additionally, on November 14, 2022, the Board approved and the Company executed an amendment to the Company’s Amended and Restated Bylaws solely to reflect the Name Change (the “Bylaws Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000080","anchor_url":"https://secwatch.observer/filing/0001005286-22-000080#claim-95627fccc5bc5faaf6c7035b3c7c105972d157da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000080/0001005286-22-000080-index.htm"},{"fact_type":"governance_change","fact_key":"e3a320270b2951c3db33ced63f5f2cf6e02971c6","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2022-11-14","item_codes_triggered":["5.03"],"summary_text":"Changed company name from Landec Corporation to Lifecore Biomedical, Inc. by filing an amendment to the Certificate of Incorporation."},"claim":"LIFECORE BIOMEDICAL, INC. DE: Changed company name from Landec Corporation to Lifecore Biomedical, Inc. by filing an amendment to the Certificate of Incorporation (effective 2022-11-14).","evidence_excerpt":"On November 14, 2022, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”), filed an amendment to the Company’s Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware to change the Company’s name from Landec Corporation to Lifecore Biomedical, Inc. (the “Name Change”), which was approved by the board of directors (the “Board”) of the Company, and which became effective on November 14, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000080","anchor_url":"https://secwatch.observer/filing/0001005286-22-000080#claim-e3a320270b2951c3db33ced63f5f2cf6e02971c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000080/0001005286-22-000080-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3b8f84d32f5c79f3c1cd0283b253683e83799985","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of amendment to the Landec Corporation 2019 Stock Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,698,258","subject":null,"votes_abstain":"16,615","votes_against":"3,096,263","votes_for":"18,487,481","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of amendment to the Landec Corporation 2019 Stock Incentive Plan.","evidence_excerpt":"Stockholders approved the amendment to the Landec Corporation 2019 Stock Incentive Plan, with votes as follows: For Against Abstain Broker Non-Votes 18,487,481 3,096,263 16,615 2,698,258","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000065","anchor_url":"https://secwatch.observer/filing/0001005286-22-000065#claim-3b8f84d32f5c79f3c1cd0283b253683e83799985","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4fdf9071a291519893100a8c308ddc9a8b8de0d2","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of non-binding advisory proposal on the executive compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,698,258","subject":null,"votes_abstain":"324,090","votes_against":"1,086,858","votes_for":"20,189,411","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of non-binding advisory proposal on the executive compensation of the Company's named executive officers.","evidence_excerpt":"Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: For Against Abstain Broker Non-Votes 20,189,411 1,086,858 324,090 2,698,258","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000065","anchor_url":"https://secwatch.observer/filing/0001005286-22-000065#claim-4fdf9071a291519893100a8c308ddc9a8b8de0d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9219ef775f1b96ae5298aa11ce4d832c830c093e","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-28","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"44,006","votes_against":"8,975","votes_for":"24,245,636","votes_withheld":null}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023 at the 2023-05-28 meeting.","evidence_excerpt":"Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023, with votes as follows: For Against Abstain 24,245,636 8,975 44,006","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000065","anchor_url":"https://secwatch.observer/filing/0001005286-22-000065#claim-9219ef775f1b96ae5298aa11ce4d832c830c093e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7fa2df393679d0cb12bad053f89f633327b93285","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of three directors for a two-year term","proposal_type":"director_election","results":[{"broker_non_votes":"2,698,258","subject":"Katrina L. Houde","votes_abstain":null,"votes_against":null,"votes_for":"15,180,997","votes_withheld":"6,419,362"},{"broker_non_votes":"2,698,258","subject":"Nelson Obus","votes_abstain":null,"votes_against":null,"votes_for":"17,689,049","votes_withheld":"3,911,310"},{"broker_non_votes":"2,698,258","subject":"Jeffrey L. Edwards","votes_abstain":null,"votes_against":null,"votes_for":"17,743,088","votes_withheld":"3,857,271"}]},"claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Election of three directors for a two-year term.","evidence_excerpt":"The voting results for the election of directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Katrina L. Houde 15,180,997 6,419,362 2,698,258 Nelson Obus 17,689,049 3,911,310 2,698,258 Jeffrey L. Edwards 17,743,088 3,857,271 2,698,258","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001005286-22-000065","anchor_url":"https://secwatch.observer/filing/0001005286-22-000065#claim-7fa2df393679d0cb12bad053f89f633327b93285","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm"},{"fact_type":"executive_change","fact_key":"8b0ed906dc","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tonia Pankopf departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-8b0ed906dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"51f1d5f1c0","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Deborah Carosella departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-51f1d5f1c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"dc7be2d885","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Catherine A. Sohn departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-dc7be2d885","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"86c8fccd21","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Powell departed as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-86c8fccd21","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"7468098228","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-10","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"James G. Hall was appointed as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On August 10, 2022, the Board appointed James G. Hall as the Company’s Chief Executive Officer and as a director of the Board, succeeding Dr. Albert Bolles, to serve in such capacities until his successor is duly elected and qualified or until his earlier death, resignation or removal.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-7468098228","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"13e6df73d5","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-08-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-08-10","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"James G. Hall","successor_named":true},"claim":"Albert Bolles resigned as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"In accordance with the Separation Agreement, Dr. Bolles resigned as the Company’s Chief Executive Officer and as a director of the Board of Directors of the Company (the “Board), effective immediately, to transition to serve as President of Curation Foods, Inc., a wholly owned subsidiary of the Company.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-22-000029","anchor_url":"https://secwatch.observer/filing/0001005286-22-000029#claim-13e6df73d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm"},{"fact_type":"executive_change","fact_key":"7d80c90de8","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-01-24T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ray Diradoorian was elected as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On January 20, 2022 the Board of Directors (the “Board”) of Landec Corporation (the “Company”) increased the size of the Board to 11 members and elected Ray Diradoorian to serve as a member of the Board, Class 2 Director and member of the Lifecore Focus Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001005286-22-000013","anchor_url":"https://secwatch.observer/filing/0001005286-22-000013#claim-7d80c90de8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000013/0001005286-22-000013-index.htm"},{"fact_type":"executive_change","fact_key":"b5f5bfafed","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2021-10-15T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2021-10-11","interim":false,"role":"Vice President of the Company and Senior Vice President of Supply Chain","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Timothy P. Burgess departed as Vice President of the Company and Senior Vice President of Supply Chain at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On October 11, 2021, Landec Corporation (the “Company”), Curation Foods, Inc. (“Curation Foods”), a wholly owned subsidiary of the Company, and Timothy P. Burgess, Vice President of the Company and Senior Vice President of Supply Chain with Curation Foods, agreed to separate his employment, effective October 11, 2021","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-21-000061","anchor_url":"https://secwatch.observer/filing/0001005286-21-000061#claim-b5f5bfafed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528621000061/0001005286-21-000061-index.htm"},{"fact_type":"executive_change","fact_key":"b5be505e05","cik":1005286,"ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2021-07-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-07-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Patrick D. Walsh resigned as Director at LIFECORE BIOMEDICAL, INC. DE.","evidence_excerpt":"On July 27, 2021, Mr. Patrick D. Walsh, member of the Board of Directors (the “Board”) of the Company, notified the Company of his resignation from the Board effective as of such date.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001005286-21-000040","anchor_url":"https://secwatch.observer/filing/0001005286-21-000040#claim-b5be505e05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528621000040/0001005286-21-000040-index.htm"}]}